Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes.

Baowen YuMoran HuWanzi JiangYizhe MaJingya YeQinyi WuWen GuoYan SunMin ZhouYiwen XuZhoulu WuYiwen WangSin Man LamGuanghou ShuiJingyu GuJohn Zhong LiZhenzhen Fu Yingyun Gong Hongwen Zhou

Published in: Lipids in health and disease (2023)

The First Affiliated Hospital of Nanjing Medical University's Institutional Review Board authorized this study protocol, and all participants provided written informed consent (2014-SR-003) prior to study entry.

Keyphrases

study protocol
healthcare
randomized controlled trial
metabolic syndrome
type diabetes
insulin resistance
clinical trial
weight gain
open label
emergency department
adipose tissue
body mass index
acute care
double blind